Bionano Genomics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.5M | $30.8M | $36.1M | $27.8M | $18.0M | $8.5M | $10.1M | $12.0M |
| Cost of Revenue | $15.3M | $30.4M | $26.6M | $21.9M | $14.1M | $5.7M | $6.8M | $8.7M |
| Gross Profit | $13.2M | $380.0K | $9.6M | $5.9M | $3.9M | $2.8M | $3.4M | $3.3M |
| Gross Margin | 46.3% | 1.2% | 26.5% | 21.4% | 21.5% | 32.6% | 33.2% | 27.4% |
| Operating Expenses | ||||||||
| Research & Development | $11.4M | $24.8M | $54.0M | $49.0M | $22.5M | $10.3M | $9.1M | $9.5M |
| SG&A Expense | $35.2M | $51.9M | $92.8M | $88.6M | $58.5M | $31.1M | $20.2M | $14.2M |
| Operating Income | $-33.3M | $-104.0M | $-215.2M | $-131.7M | $-77.1M | $-38.6M | $-25.9M | $-20.4M |
| Operating Margin | -116.9% | -337.9% | -596.0% | -473.7% | -428.8% | -453.4% | -255.4% | -170.1% |
| Interest Expense | — | — | $5.1M | $298.0K | $927.0K | $2.5M | $2.3M | $1.4M |
| Pretax Income | $-26.3M | $-112.0M | $-232.4M | $-130.7M | $-78.2M | $-41.1M | $-29.8M | $-18.5M |
| Income Tax Expense | $67.0K | $33.0K | $62.0K | $1.9M | $-5.7M | $29.0K | $21.0K | $15.5K |
| Net Income | $-26.4M | $-112.0M | $-232.5M | $-132.6M | $-72.4M | $-41.1M | $-29.8M | $-18.5M |
| Net Margin | -92.6% | -364.0% | -643.7% | -476.9% | -402.8% | -483.4% | -294.3% | -154.1% |
| EPS (Basic) | $-4.85 | $-22.03 | $-51.08 | $-0.57 | $-0.03 | $-0.05 | $-0.25 | $-0.33 |
| EPS (Diluted) | $-4.85 | $-22.03 | $-51.08 | $-0.57 | $-0.03 | $-0.05 | $-0.25 | $-0.33 |
| Shares Outstanding (Basic) | 5.4M | 5.1M | 4.6M | 231.4M | 2.21B | 1.52B | 274.2M | 80.4M |
| Shares Outstanding (Diluted) | 5.4M | 5.1M | 4.6M | 231.4M | 2.21B | 1.52B | 274.2M | 80.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |